US 10,376,597 B2
Targeting tumor cells with chemotherapeutic agents conjugated to matriptase antibodies
Siang-Yo Lin, East Brunswick, NJ (US); Joseph R. Bertino, Branford, CT (US); and Chen-Yong Lin, Falls Church, VA (US)
Assigned to RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY, New Brunswick, NJ (US); and GEORGETOWN UNIVERSITY, Washington, DC (US)
Filed by Rutgers, The State University of New Jersey, New Brunswick, NJ (US); and Georgetown University, Washington, DC (US)
Filed on Dec. 1, 2017, as Appl. No. 15/829,173.
Application 15/829,173 is a continuation of application No. 15/075,008, filed on Mar. 18, 2016, granted, now 9,849,192.
Application 15/075,008 is a continuation in part of application No. 13/510,801, abandoned, previously published as PCT/US2010/057235, filed on Nov. 18, 2010.
Claims priority of provisional application 61/293,030, filed on Jan. 7, 2010.
Claims priority of provisional application 61/262,373, filed on Nov. 18, 2009.
Prior Publication US 2018/0177889 A1, Jun. 28, 2018
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/00 (2006.01); A61K 47/68 (2017.01); C07K 16/40 (2006.01)
CPC A61K 47/6851 (2017.08) [A61K 47/6803 (2017.08); A61K 47/6809 (2017.08); A61K 47/6871 (2017.08); C07K 16/40 (2013.01); A61K 2039/505 (2013.01); C07K 2317/77 (2013.01)] 10 Claims
 
1. An immunoconjugate comprising an antibody or antigen-binding fragment thereof that binds matriptase in a form selectively expressed on cancer cells, said antibody or fragment covalently linked to a chemotherapeutic agent, wherein said antibody or fragment binds a complex between activated matriptase and its inhibitor HAI-1, wherein said antibody is M69 or an antigen binding fragment thereof, or is a chimeric antibody that comprises the variable regions of M69, or is a humanized antibody that comprises the variable regions of M69.